Descargar PDF
Linfoma de células T/Natural Killers extranodal: reporte de un caso
Resumen
Introducción: Los linfomas extranodales de células T/Natural Killers son enfermedades poco frecuentes con una mayor incidencia en las regiones de Asia Oriental y América Central y del Sur y están asociados con el virus de Epstein-Barr. Estas neoplasias tienen tendencia a afectar la línea media facial, principalmente las regiones nasales y paranasales. Estas enfermedades desarrollan un patrón de crecimiento angiocéntrico con necrosis. Estos linfomas tienen un comportamiento agresivo y una elevada mortalidad.
Objetivo: El presente trabajo tiene por objetivo presentar un caso raro de linfoma de células T/NK que debe ser tenido en cuenta pues su diagnóstico tardío influye en la alta letalidad y pobre sobrevida
Presentación del caso: Presentamos un caso de linfoma extranodal de células T/Natural Killers. Varón de 21 años con cuadro febril de larga data de evolución (3 meses) obstrucción nasal, pérdida de peso e hinchazón del arco cigomático. Acompañado de infiltración tumoral, destrucción del paladar y secreción purulenta a través del ojo izquierdo. Los síntomas y signos transcurren en un período de 4 meses aproximadamente, con un deterioro progresivo del paciente.
Conclusión: Incluso cuando el linfoma extraganglionar de células T/Natural Killers es una enfermedad poco frecuente, tiene un curso clínico agresivo con mal pronóstico y supervivencia. Por lo tanto, debe considerarse en el diagnóstico diferencial del aumento de volumen nasal o paranasal.
Palabras clave
Referencias
Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk. 2018 Jul 1;18(7):475–9.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022 36:7 [Internet]. 2022 Jun 22 [cited 2022 Aug 28];36(7):1720–48. Available from: https://www.nature.com/articles/s41375-022-01620-2
Asano N, Kato S, Nakamura S. Epstein–Barr virus-associated natural killer/T-cell lymphomas. Best Pract Res Clin Haematol. 2013 Mar;26(1):15–21.
Bajor-Dattilo EB, Pittaluga S, Jaffe ES. Pathobiology of T-cell and NK-cell lymphomas. Best Pract Res Clin Haematol. 2013 Mar;26(1):75–87.
Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020 Apr 1;7(4):e284–94.
Peng RJ, Han BW, Cai QQ, Zuo XY, Xia T, Chen JR, et al. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia [Internet]. 2019;33(6):1451–62. Available from: https://doi.org/10.1038/s41375-018-0324-5
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar 1;65(2):87–108.
Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiology Biomarkers & Prevention. 2016 Jan 12;25(1):16 LP – 27.
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Sep 1;n/a-n/a.
William BM, Armitage JO. International analysis of the frequency and outcomes of NK/T-cell lymphomas. Best Pract Res Clin Haematol. 2013 Mar;26(1):23–32.
Jhuang JY, Chang ST, Weng SF, Pan ST, Chu PY, Hsieh PP, et al. Extranodal natural killer/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumors. Hum Pathol. 2015 Feb;46(2):313–21.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 1 [cited 2022 Jun 6];71(3):209–49. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21660
Saleem A, Natkunam Y. Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. International Journal of Molecular Sciences 2020, Vol 21, Page 1501 [Internet]. 2020 Feb 22 [cited 2022 Aug 28];21(4):1501. Available from: https://www.mdpi.com/1422-0067/21/4/1501/htm
Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. EBV and the Pathogenesis of NK/T Cell Lymphoma. Cancers 2021, Vol 13, Page 1414 [Internet]. 2021 Mar 19 [cited 2022 Aug 28];13(6):1414. Available from: https://www.mdpi.com/2072-6694/13/6/1414/htm
de Mel S, Soon GST, Mok Y, Chung TH, Jeyasekharan AD, Chng WJ, et al. The genomics and molecular biology of natural killer/T-cell lymphoma: Opportunities for translation. Int J Mol Sci [Internet]. 2018;19(7). Available from: www.mdpi.com/journal/ijms
Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020 Feb 1;21(2):306–16.
Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016 Sep 1;17(9):1240–7.
Dong G, Liu X, Wang L, Yin W, Bouska A, Gong Q, et al. Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma. Leukemia 2022 36:8 [Internet]. 2022 Jun 13 [cited 2022 Aug 28];36(8):2064–75. Available from: https://www.nature.com/articles/s41375-022-01623-z
Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood [Internet]. 2018 Sep 13 [cited 2022 Aug 11];132(11):1146–58. Available from: https://ashpublications.org/blood/article/132/11/1146/39381/Oncogenic-activation-of-the-STAT3-pathway-drives
Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell. 2020 Mar 16;37(3):403-419.e6.
Zhang Y, Li C, Xue W, Zhang M, Li Z. Frequent Mutations in Natural Killer/T Cell Lymphoma. Cellular Physiology and Biochemistry [Internet]. 2018 Sep 1 [cited 2022 Aug 11];49(1):1–16. Available from: https://www.karger.com/Article/FullText/492835
Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, et al. Extranodal NK/T-cell Lymphoma, Nasal Type: A Report of 73 Cases at MD Anderson Cancer Center. Am J Surg Pathol [Internet]. 2013;37(1). Available from: http://journals.lww.com/ajsp/Fulltext/2013/01000/Extranodal_NK_T_cell_Lymphoma,_Nasal_Type__A.2.aspx
Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, et al. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. Journal of Clinical Oncology. 2016 Oct 3;
Tse E, Kwong YL. NK/T-cell lymphomas. Best Pract Res Clin Haematol. 2019 Sep 1;32(3):253–61.
Suzuki R. Pathogenesis and Treatment of Extranodal Natural Killer/T-Cell Lymphoma. Semin Hematol. 2014 Jan;51(1):42–51.
Tse E, Au-Yeung R, Kwong YL. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. https://doi.org/101080/1747408620191660640 [Internet]. 2019 Nov 2 [cited 2022 Aug 28];12(11):927–35. Available from: https://www.tandfonline.com/doi/abs/10.1080/17474086.2019.1660640
Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood [Internet]. 2018 Jun 7 [cited 2022 Aug 28];131(23):2528–40. Available from: https://ashpublications.org/blood/article/131/23/2528/36945/Advances-in-the-treatment-of-extranodal-NK-T-cell
van Doesum JA, Niezink AGH, Huls GA, Beijert M, Diepstra A, van Meerten T. Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment. Hemasphere [Internet]. 2021 Feb 12 [cited 2022 Aug 28];5(2). Available from: /pmc/articles/PMC7806244/
Wang X, Hu J, Dong M, Ding M, Zhu L, Wu J, et al. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. Clin Transl Sci [Internet]. 2021 Jan 1 [cited 2022 Aug 28];14(1):405–11. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/cts.12893
Añadir comentario
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
La revista está: Certificada por el CITMA